{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:08:07Z","timestamp":1791054487945,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,3,11]],"date-time":"2013-03-11T00:00:00Z","timestamp":1362960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We evaluated the efficacy and safety of istradefylline, a selective adenosine A<jats:sub>2A<\/jats:sub> receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double\u2010blind manner in Parkinson's disease patients with motor complications in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 373 subjects were randomized to receive placebo (n\u2009=\u2009126), istradefylline 20 mg\/day (n\u2009=\u2009123), or istradefylline 40 mg\/day (n\u2009=\u2009124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The change in daily OFF time was significantly reduced in the istradefylline 20 mg\/day (\u22120.99 hours, <jats:italic>P<\/jats:italic>\u2009=\u2009.003) and istradefylline 40 mg\/day (\u22120.96 hours, <jats:italic>P<\/jats:italic>\u2009=\u2009.003) groups compared with the placebo group (\u22120.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg\/day, 13.0%; istradefylline 40 mg\/day, 12.1%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment. \u00a9 2013 <jats:italic>Movement<\/jats:italic> Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.25418","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T04:30:24Z","timestamp":1363149024000},"page":"1138-1141","source":"Crossref","is-referenced-by-count":207,"title":["Adenosine A<sub>2A<\/sub> receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease"],"prefix":"10.1002","volume":"28","author":[{"given":"Yoshikuni","family":"Mizuno","sequence":"first","affiliation":[{"name":"Kitasato University School of Medicine  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Rehabilitation Hananoie Hospital Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Japanese Istradefylline Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10031"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_5.S1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000095211.71092.A0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.6.729"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.643869"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130051146"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410430415"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.8.1673"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7350"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000081227.84197.0B"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000073136.00548.D4"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21315"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313834.22171.17"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22095"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.09.023"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23107"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.3.181"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(00)00250-5"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20539"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25418","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:16:46Z","timestamp":1760966206000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,11]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1002\/mds.25418"],"URL":"https:\/\/doi.org\/10.1002\/mds.25418","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,11]]}}}